4. Pain
Knowledge Workers are expensive
Trend has been to “offshore” everything
from software development to
telephone based customer service
But this offers only an incremental cost
improvement…
5. Solution
With Synthetic Intelligence, SI replaces
the human with not just a machine, but
a “synthetic human” intelligence
This offers an order of magnitude
improvement in
cost
speed
and accuracy
6. Initial Markets/Roll-out
3 Phase market vertical roll-out
1st Market Vertical– legal industry
2nd Market Vertical– recruiting industry
3rd Market Vertical– VC industry
7. Case Study
Venture Capital-- Implementing SI
achieved the following:
Shortened time to decision by 10,000%
Order of magnitude reduction of # of general
partners required for $1B fund
Probability of success increased from 1 in 10 to 2 in
10, a 100% increase
Same math can be applied to the legal and
recruiting community…
9. 2nd Application
Biotechnology drug discovery
Pain: hard to discover/validate drug
targets using conventional methods
Solution: SI solves this by making
decisions on which targets to run with in
all three stages of product
development, pre-clinical & clinical drug
development
10. The Product
Biotech drug discovery
Based on same platform technology
Targets will be identified
Once match is made, will file IND
Then go to clinical trials in less than 6
months
11. Current IND Product Candidates
C3PO
C3PO is a bi-specific monoclonal antibody targeting a tumor specific
antigen (Galactica) which is over-expressed on adenocarcinomas such as
pancreatic, ovarian and colon cancers.
C3PO is constructed of a proprietary linker joining two antibodies; one
binding to the R2D2 receptor on immune T cells (cytolytic effector) and the
other to Galactica on cancer cells.
Once bound to Galactica on the cancer cells, the proprietary linker facilitates
the killing of primary and metastasized tumor cells by the T cell
C3PO has been shown to be effective in vivo in reducing growth in
colorectal tumors with specificity to those tumors with Galactica positive
antigens
12. Team
CEO– “X” (will disclose name upon
funding) currently leader of Fortune 10
company, willing to leave the role for
this start-up once we receive funding
VP Sales– “Y”, 30 years of sales
experience, very good.
Rest of Org Chart-- TBD
13. Strategic Advisory
Vince Fulmer Board
MIT Enterprise Forum Chair Emeritus
entrepreneurial expert
author of the phrase, “We are students and practitioners
of entrepreneurship. We are specialists in promoting the
field of technology entrepreneurship”
Weekend warrior and winner of MIT EF body builder
Competition, 2004
Trish Fleming
Executive Director, MIT Enterprise Forum
Glad-handing networker extraordinaire
Fashion Diva, and E! Entertainment fashion
commentator replacement for Joan Rivers
15. Funding
Currently seeking 15M
Use of funds
Accrued wages (particularly founders)
Infrastructure (office space, furniture, telecom)
US
Europe
Asia
Bali